JP2023535730A5 - - Google Patents

Info

Publication number
JP2023535730A5
JP2023535730A5 JP2023504555A JP2023504555A JP2023535730A5 JP 2023535730 A5 JP2023535730 A5 JP 2023535730A5 JP 2023504555 A JP2023504555 A JP 2023504555A JP 2023504555 A JP2023504555 A JP 2023504555A JP 2023535730 A5 JP2023535730 A5 JP 2023535730A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
cell
formula
permeable complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023504555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023535730A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/043213 external-priority patent/WO2022020810A1/en
Publication of JP2023535730A publication Critical patent/JP2023535730A/ja
Publication of JP2023535730A5 publication Critical patent/JP2023535730A5/ja
Pending legal-status Critical Current

Links

JP2023504555A 2020-07-24 2021-07-26 Covid-19の3成分ワクチン Pending JP2023535730A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063056465P 2020-07-24 2020-07-24
US63/056,465 2020-07-24
PCT/US2021/043213 WO2022020810A1 (en) 2020-07-24 2021-07-26 A three component vaccine for covid-19

Publications (2)

Publication Number Publication Date
JP2023535730A JP2023535730A (ja) 2023-08-21
JP2023535730A5 true JP2023535730A5 (cg-RX-API-DMAC10.html) 2024-05-27

Family

ID=79728449

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023504555A Pending JP2023535730A (ja) 2020-07-24 2021-07-26 Covid-19の3成分ワクチン

Country Status (7)

Country Link
US (1) US20240148858A1 (cg-RX-API-DMAC10.html)
EP (1) EP4185331A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023535730A (cg-RX-API-DMAC10.html)
CN (1) CN116724118A (cg-RX-API-DMAC10.html)
AU (1) AU2021310952A1 (cg-RX-API-DMAC10.html)
CA (1) CA3189834A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022020810A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250177559A1 (en) * 2022-03-09 2025-06-05 The Board Of Trustees Of The Leland Stanford Junior University Branched lipid charge-altering releasable transporters for nucleic acid delivery
EP4493197A4 (en) * 2022-03-17 2026-03-18 Univ Leland Stanford Junior COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN TRANSLATION FROM RECOMBED CIRCULAR RNA
US20260014246A1 (en) * 2022-07-11 2026-01-15 The Uab Research Foundation Treatment methods for viral infections
CN121002058A (zh) * 2022-12-09 2025-11-21 艾布维兹生物公司 针对SARS-CoV-2及其变体的抗体或其片段

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9909915A (pt) * 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
EP3302501B1 (en) * 2015-05-29 2021-09-22 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
JP7179715B2 (ja) * 2016-07-27 2022-11-29 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 核酸送達用の崩壊性細胞透過性複合体
US12215341B2 (en) * 2018-11-09 2025-02-04 The Board Of Trustees Of The Leland Stanford Junior University Hybrid immolative cell-penetrating complexes for nucleic acid delivery
JP7693548B2 (ja) * 2019-02-01 2025-06-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 肺への核酸送達のための犠牲細胞透過性複合体
CN111217918B (zh) * 2020-03-04 2020-11-10 中山大学 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗

Similar Documents

Publication Publication Date Title
JP7625637B2 (ja) B型肝炎ウイルス感染のためのRNAi薬
ES2572563T3 (es) Oligonucleótidos inmunoestimulantes
JP3273135B2 (ja) 新規ペプチド核酸
JP7763907B2 (ja) B型肝炎ウイルス感染のためのRNAi薬
BG109985A (bg) Метод за лечение на астма, усложнена от инфекциозно заболяване
JP2025072507A5 (cg-RX-API-DMAC10.html)
JP2020018299A (ja) 修飾されたサブユニット間結合および/または末端基を有するオリゴヌクレオチドアナログ
JP2003535146A5 (cg-RX-API-DMAC10.html)
CN111527207A (zh) GalNAc衍生物
JP2011504486A5 (cg-RX-API-DMAC10.html)
AU2013262415B2 (en) Oligonucleotide chelate complex methods
CN110023321A (zh) 多核苷酸构建体
EA008741B1 (ru) Аналоги олигонуклеотидов с-класса с улучшенной иммуностимулирующей эффективностью
JP2006109846A (ja) 抗腫瘍性アンチセンスオリゴヌクレオチド
TWI298328B (en) Polyamide nucleic acid derivatives, and agents and process for preparing them
JP2022526267A5 (cg-RX-API-DMAC10.html)
JP2004501211A5 (cg-RX-API-DMAC10.html)
MXPA04000162A (es) Metodos para incrementar la eficacia in vivo de oligonucleotidos e inhibir la inflamacion en mamiferos.
JP2004526737A5 (cg-RX-API-DMAC10.html)
JP5428017B2 (ja) ワクチン剤
CN119895041A (zh) 优化的2’-修饰的核糖衍生物及使用方法
WO2020246584A1 (ja) ペプチド核酸を基盤としたアジュバント
WO2024163918A1 (en) Mrna vaccine for herpes simplex virus
WO2022215737A1 (ja) アジュバント活性増強剤及びアジュバント組成物
JP2004522722A (ja) 化合物